Skip to main content
Terug
AVBP logo

ArriVent BioPharma, Inc. Common Stock

Datakwaliteit: 100%
AVBP
NASDAQ Healthcare Biotechnology
€ 22,18
▲ € 0,16 (0,73%)
Marktkapitalisatie: 980,39M
Dagbereik
€ 21,73 € 22,72
52-Weeksbereik
€ 15,47 € 27,22
Volume
483.405
50D / 200D Gem.
€ 22,89 / € 21,19
Vorige Slotkoers
€ 22,02

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -5,9 0,4
P/B 3,2 2,9
ROE % -58,9 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -160,59M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-58,88%
ROIC-43,34%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Current Ratio12,83
Interest Coverage0,00

Waardering

P/E Ratio
-5,90
P/B Ratio3,19
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -166,31M
ROE -58,88% ROA -49,92%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -160,59M
ROIC -43,34% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 12,83
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -5,90 P/B Ratio 3,19
P/S Ratio N/A PEG Ratio -0,07
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 980,39M Enterprise Value 934,87M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -166,31M -80,49M -69,33M -36,91M -51,61M
EPS (Diluted) -4,32 -2,56 -2,17 -1,10 -40,44
Gross Profit 0,0 0,0 0,0 0,0 0,0
Operating Income -177,53M -94,31M -74,59M -36,91M -8,70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 333,17M 274,94M 163,10M 182,83M 43,04M
Total Liabilities 25,95M 17,29M 11,80M 8,37M 1,82M
Shareholders' Equity 307,22M 257,65M 151,30M 174,46M 41,22M
Total Debt 14.000,0 176.000,0 317.000,0 139.000,0 0,0
Cash & Equivalents 45,54M 74,29M 150,39M 163,37M 37,28M
Current Assets 332,90M 226,98M 159,97M 182,62M 42,95M
Current Liabilities 25,95M 17,27M 11,62M 8,36M 1,82M